Phathom Pharmaceuticals, Inc. filings document financial reporting, governance, capital structure and product-development disclosures for a Nasdaq-listed biopharmaceutical company focused on gastrointestinal diseases. Form 8-K reports include quarterly and annual results, preliminary financial information, material agreements, financing-related updates, and other event disclosures tied to VOQUEZNA® commercialization and clinical development.
Proxy materials cover board matters, executive compensation, equity awards and shareholder voting items. The filing record also describes registered common stock, risk-oriented forward-looking statements, and clinical or publication updates involving VOQUEZNA in GERD, non-erosive reflux disease and eosinophilic esophagitis.
Phathom Pharmaceuticals reported a Form 4 filing on June 28, 2025, disclosing stock option grants to Anne Marie Cook, the company's Chief Legal Officer & Corporate Secretary.
Key transaction details:
- Granted 210,000 stock options to purchase common stock
- Exercise price set at $9.47 per share
- Grant date: June 23, 2025
- Expiration date: June 22, 2035
The options follow a 4-year vesting schedule: 25% vests on June 23, 2026, with the remainder vesting in equal monthly installments over the following three years, contingent on continuous service. This grant appears to be part of the company's executive compensation program.
Anne Marie Cook has filed an initial Form 3 Statement of Beneficial Ownership following her appointment as Chief Legal Officer & Corporate Secretary at Phathom Pharmaceuticals (PHAT). The filing, dated June 28, 2025, discloses her beneficial ownership status as of June 23, 2025.
Key details of the filing:
- Cook currently owns no securities of Phathom Pharmaceuticals
- No derivative securities (options, warrants, etc.) are reported as beneficially owned
- The filing is made as an individual submission, not as part of a group
- Direct ownership form is indicated for the zero securities position
This Form 3 filing is a standard regulatory requirement for new officers, directors, and 10% shareholders under Section 16(a) of the Securities Exchange Act of 1934, establishing a baseline for future transaction reporting.